Generate Biomedicines, Inc. (GENB) Stock Forecast
Data as of Aug 8, 2026Healthcare · Current price $14.20 (+2.23%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
GENB vs Sector & Market
| Metric | GENB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 2 | 8 | 18 |
| Target Upside | +65.5% | +16286.4% | +14.7% |
| P/E Ratio | -3.07 | 3.59 | 36.06 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $20M | $26M | $33M | 5 |
| 2027-12-31 | $4M | $21M | $35M | 5 |
| 2028-12-31 | $47M | $92M | $135M | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.34 | $-2.01 | $-1.66 | 3 |
| 2027-12-31 | $-2.32 | $-2.02 | $-1.73 | 3 |
| 2028-12-31 | $-2.50 | $-2.21 | $-1.92 | 2 |
Frequently Asked Questions
What is the analyst consensus for GENB?
The consensus among 2 analysts covering Generate Biomedicines, Inc. (GENB) is Buy with an average price target of $23.50.
What is the highest price target for GENB?
The highest analyst price target for GENB is $25.00.
What is the lowest price target for GENB?
The lowest analyst price target for GENB is $22.00.
How many analysts cover GENB?
2 analysts have issued ratings for Generate Biomedicines, Inc. in the past 12 months.
Is GENB a buy or sell right now?
Based on 2 analyst ratings, GENB has a consensus rating of Buy (2.00/5) with a +65.5% upside to the consensus target of $23.50.
What are the earnings estimates for GENB?
Analysts estimate GENB will report EPS of $-2.01 for the period ending 2026-12-31, with revenue estimated at $26M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.